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Genome-wide association studies (GWASs) have revealed SNP rs889312 on 5q11.2 to be associatedwith breast cancer risk inwomen of Eu-
ropean ancestry. In an attempt to identify the biologically relevant variants, we analyzed 909 genetic variants across 5q11.2 in 103,991
breast cancer individuals and control individuals from52 studies in theBreastCancer AssociationConsortium.Multiple logistic regression
analyses identified three independent risk signals: the strongest associations were with 15 correlated variants (iCHAV1), where theminor
allele of the best candidate, rs62355902, associated with significantly increased risks of both estrogen-receptor-positive (ERþ: odds ratio
[OR] ¼ 1.24, 95% confidence interval [CI] ¼ 1.21–1.27, ptrend ¼ 5.73 1044) and estrogen-receptor-negative (ER: OR ¼ 1.10, 95% CI ¼
1.05–1.15, ptrend ¼ 3.0 3 104) tumors. After adjustment for rs62355902, we found evidence of association of a further 173 variants
(iCHAV2) containing three subsets with a range of effects (the strongest was rs113317823 [pcond ¼ 1.61 3 105]) and five variants
composing iCHAV3(leadrs11949391;ERþ:OR¼0.90, 95%CI¼0.87–0.93,pcond¼1.43104). Twenty-sixpercentof theprioritizedcandi-
date variants coincided with four putative regulatory elements that interact with theMAP3K1 promoter through chromatin looping and
affectMAP3K1 promoter activity. Functional analysis indicated that the cancer risk alleles of four candidates (rs74345699 and rs62355900
[iCHAV1], rs16886397 [iCHAV2a], and rs17432750 [iCHAV3]) increasedMAP3K1 transcriptional activity. Chromatin immunoprecipita-
tion analysis revealed diminishedGATA3 binding to theminor (cancer-protective) allele of rs17432750, indicating amechanism for its ac-
tion. We propose that the cancer risk alleles act to increaseMAP3K1 expression in vivo and might promote breast cancer cell survival.Introduction
One of the first genome-wide association studies (GWASs)
for breast cancer (MIM 114480) susceptibility identified a
5q11.2 SNP (rs889312) associated with risk of breast cancer
in women of European ancestry.1 In the most recent
analyses by the Breast Cancer Association Consortium
(BCAC), the minor allele of rs889312 was associated with
a per-allele odds ratio (OR)¼ 1.12 (95% confidence interval
[CI]¼ 1.10–1.15; ptrend¼ 1.83 1026).2 The associationwas
stronger for estrogen-receptor-positive (ERþ) disease (OR ¼
1.14, 95% CI ¼ 1.11–1.17, p ¼ 1.1 3 1026 in the most
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Thereceptor-negative (ER) disease (OR ¼ 1.06, 95% CI ¼
1.03–1.10, p ¼ 0.0024) and triple negative disease (OR ¼
1.11, 95% CI ¼ 1.02–1.20, p ¼ 0.016).3 SNP rs889312 was
also reported to be associated with an increased breast can-
cer risk in carriers of BRCA2 (MIM 600185) mutations.4
The GWAS SNP rs889312 lies approximately 80 kb
centromeric toMAP3K1 (MIM 600982), the gene encoding
mitogen-activated protein kinase kinase kinase 1, also
known as MEK kinase 1 (MEKK1), a stress-induced serine/
threonine kinase with apparent dual functions: MEKK1
induces cell proliferation through a RAS-RAF-MEK-ERK
signaling pathway,5 but upon caspase cleavage, it generates
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MEKK1 regulates transcription of key cancer-related genes,
such as MYC8 (MIM 190080), TP539 (MIM 191170), and
JUN10 (MIM 165160), through its signal-transduction
pathway. There is already evidence of a role for MAP3K1
in breast cancer pathogenesis: MAP3K1 driver mutations
have been observed in luminal A and B type breast
tumors,11 and MAP3K1 expression has been associated
with specific breast tumor subtypes.12
In this study, we performed genetic epidemiological
analyses on all common variants at 5q11.2, together
with in silico and in vitro analyses of candidate causal
variants, and identified strong candidates that we propose
are functionally related to breast cancer risk. Specifically,
we provide evidence that these associations are mediated
through MAP3K1.Material and Methods
SNP Selection and Genotyping
Using the March 2010 release of the 1000 Genomes Project,13 we
searched a 305 kb interval on 5q11.2 (GRCh37 positions
55,983,657–56,288,810) and identified all SNPs with a minor
allele frequency (MAF) > 0.02 in Europeans. SNPs with an Illu-
mina designability score > 0.8 (and r2 > 0.1 with rs889312),
together with a tagging set (r2 > 0.9) for all other known SNPs
in the interval, were selected for inclusion on the iCOGS custom
array.2 A total of 352 SNPs, of which 300 passed postgenotyping
quality-control criteria, were selected.2 For improvement of SNP
coverage across the locus, 16 further SNPs selected from the
October 2010 release of the 1000 Genomes Project were geno-
typed in a subset of two BCAC studies (SEARCH and the combined
Copenhagen studies CPGS [Copenhagen General Population
Study] and CCHS [Copenhagen City Heart Study]) by using a Flu-
idigm array according to the manufacturer’s instructions. These
two data sets, as well as IMPUTE2 and the January 2012 release
of the 1000 Genomes Project as references,14 were used for
imputing all genotypes of other common variants in this interval.
All participants provided written informed consent, and all BCAC
studies had local human ethical approvals.2 Study characteristics
and iCOGS methodology have been previously reported.2Statistical Analyses
Associations with breast cancer risk in BCAC were evaluated by a
comparison of SNP genotype frequencies in case and control indi-
viduals byunconditional logistic regression.Analyseswere adjusted
by study and seven principal components.2 The primary analysis fit
eachSNPasanallelicdose andtested for associationwitha1-degree-
of-freedom trend test (ptrend) with associated OR and 95% CI. To
identify independent risk signals, we performed stepwise condi-
tional analysis in R with the function ‘‘step,’’ which included any
variant with p value < 104 in the single-SNP analysis to calculate
the most parsimonious model with a penalty value of k ¼ 10. The
null model included study and principal components. Haplotype
analysis was performed in R with the package ‘‘haplo.stats,’’ and
the analyses were adjusted for study and principal components.Cell Lines
The normal breast epithelial cell line Bre-80 was cultured as
described previously.15 The breast cancer cell lines MCF7, T-47D,8 The American Journal of Human Genetics 96, 5–20, January 8, 2015and MDA-MB231 were cultured in RPMI 1640 medium supple-
mented with 10% fetal calf serum, antibiotics, sodium pyruvate,
and in the case of MCF7 and T-47D cells, 10 mg/ml insulin.Chromosome Conformation Capture
Chromosome conformation capture (3C) libraries were generated
with EcoRI from the cell lines above as described previously.16 3C
interactions were quantitated by quantitative PCR (qPCR) with
primers designed within the EcoRI restriction fragments spanning
the 5q11.2 risk locus (Table S1, available online). qPCR was per-
formed as described previously17 with at least two independent
3C libraries from each cell line; each experiment was quantified
in duplicate. We used two bacterial artificial clones (RP11-378G4
and RP11-1146C6) covering the 5q11.2 region to create an artifi-
cial library of ligation products in order to normalize for PCR
efficiency. As an internal control, interaction frequencies were
normalized to that of the EcoRI fragment immediately upstream
of the promoter fragment.Plasmid Construction
A MAP3K1-promoter-driven luciferase reporter construct was
generated by the insertion of a 1,928 bp fragment containing
the MAP3K1 promoter and the transcription start site (chr5:
56,109,070–56,110,997, GRch37) into the MluI and HindIII sites
of pGL3-Basic. To assist cloning, AgeI and SbfI sites were inserted
into the BamHI and SalI sites downstream of the luciferase gene.
A 1,575 bp putative regulatory element (PRE)-A fragment, a
1,765 bp PRE-B2 fragment, a 2,357 bp PRE-B3 fragment, a
2,203 bp PRE-C fragment, and a 1,519 bp PRE-D fragment were
generated by PCR using primers designed with AgeI and SbfI sites
and cloned into the modified pGL3-MAP3K1 promoter construct.
PRE-B was too large (~7 kb) to be cloned in its entirety, so three
subregions termed PRE-B1, PRE-B2, and PRE-B3 were cloned sepa-
rately. The minor alleles of individual SNPs were introduced into
promoter and PRE sequences, containing the major alleles of
any other causal candidate variants, by overlap extension PCR.
Sequencing of all constructs confirmed variant incorporation
(AGRF, Brisbane). PCR primers are listed in Table S2. For the PRE-
B1 construct, a 2,129 bp region spanning chr5: 56,028,968–
56,031,097 (GRCh37) was synthesized with AgeI and SbfI sites
incorporated at the 50 and 30 ends (GenScript, Piscataway) to assist
cloning into theMAP3K1 promoter construct. The cloned regions
are highlighted in Figure 2B.Reporter Assays and Estrogen Induction
Bre-80 and MCF7 cells were transfected with equimolar amounts
of luciferase reporter plasmids and 50 ng of pRLTK transfection
control plasmid with Lipofectamine 2000. The total amount of
transfected DNA was kept constant at 600 ng for each construct
by the addition of pUC19 as a carrier plasmid. Luciferase activity
was measured 24 hr posttransfection by the Dual-Glo Luciferase
Assay System. Normalizing firefly luciferase activity to Renilla
luciferase corrected for differences in transfection efficiency or
cell-lysate preparation. For the assays under basal conditions, the
activity of each construct was calculated in relation to the activity
(defined as 1) of the construct containing the MAP3K1 promoter
alone.
For estrogen-induction assays, we treated cells as described.18
In brief, 24 hr after plating MCF7 cells into wells, we replaced me-
dium with that containing 10 nM fulvestrant for 48 hr to inhibit
estrogen-induced gene expression and thereby create a baseline
of expression for reporter assays. Cells were then incubated with
fresh medium containing either 10 nM estrogen (17b-estradiol)
or DMSO (vehicle control) and transfected with reporter plas-
mids. Luciferase assays were performed as above after 24 hr.
Statistical significance was tested by repeated-measures ANOVA
with the Greenhouse-Geisser correction for nonsphericity
and by a subsequent Dunnett’s multiple-comparisons test in
GraphPad Prism.Chromatin Immunoprecipitation Assays
Chromatin immunoprecipitation (ChIP) assays were carried out as
previously described.19 GATA3-specific mouse monoclonal anti-
bodies (sc268) were obtained from Santa Cruz Biotech. Precipitate
and input were used in qPCR using SYBR green master mix as pre-
viously described.19 Primer sequences are listed in Table S3. Both
rs17432750 primer sets gave identical enrichment, and the iden-
tity of the larger fragment was confirmed by Sanger sequencing.
All values obtained were normalized to input, and enrichment
was given in relation to the negative CCND1 (MIM 168461) con-
trol. Allele-specific ChIP was carried out with a TaqMan SNP gen-
otyping assay (Applied Biosystems) on the ChIP material. In the
TaqMan assay, two different fluorophores were each linked to a
probe detecting the two different alleles. Each allele was subse-
quently amplified with an Applied Biosystems Real Time PCR
machine (7900HT), and the data were analyzed with the SDS
software. The SDS software converts raw data to fluorescence in-
tensity for each allele and then plots the results as a scatter graph
of allele X versus allele Y. We tested the accuracy of this assay by
genotyping known mixtures of homozygous ZR751 and T47D
(C/C) and MDA-MB0-468 (A/A) cell-line DNA (Figure S1). For
the allelic discrimination, three independent experiments were
carried out and gave similar results; a representative example is
shown.GATA3 siRNA Knockdown for Reporter Assay
GATA3 (MIM 131320; L-003781-00) and nontargeting (D-001810-
10-20) ON-TARGETplus SMARTpool siRNAs were purchased from
Thermo Scientific. For knockdown, Bre-80 cells were cotransfected
with the relevant luciferase reporter plasmids and 100 nMof either
GATA3 or nontargeting siRNAs with Lipofectamine 2000. Lucif-
erase assays were performed as described above after 24 hr. qPCR
was performed as described previously17 to validate GATA3 knock-
down (Figure S9).Analysis of Expression Quantitative Trait Loci
Analysis of expression quantitative trait loci (eQTLs) was under-
taken in two sample sets of adjacent normal breast samples from
women of European decent: the first set contained 135 samples
collected for the Molecular Taxonomy of Breast Cancer Interna-
tional Consortium (METABRIC) study,20 and the second set con-
tained 56 samples extracted from The Cancer Genome Atlas
(TCGA) breast cancer study.21 Matched gene expression (Illumina
HT-12 v3 microarray for the METABRIC data; Agilent G4502A-
07-3 microarray for the TCGA data) and germline SNP data that
were either genotyped (Affymetrix SNP 6.0) or imputed (1000
Genomes Project March 2012 data, IMPUTE 2.0) were used. Corre-
lations between all imputed and genotyped variants at the 5q11.2
locus and expression levels of eight (METABRIC) or four (TCGA)
genes present in the fine-mapped region were assessed with a
linear regression model in which an additive effect on expression
level was assumed for each copy of the rare allele. CalculationsThewere carried out with the eMap library in R on the METABRIC
data and with SNPTEST software22 on the TCGA data.Results
Genotyping of Case-Control Studies
Three hundred SNPs at the 5q11.2 locus (GRch37 positions
55,983,657–56,288,810) were successfully genotyped with
the iCOGs chip in 103,991 breast cancer case and control
individuals from 52 BCAC studies, of which 41 included
individuals of European ancestry (46,451 case and 42,599
control subjects), nine included individuals of Asian
ancestry (6,269 case and 6,624 control subjects), and two
included individuals of African American ancestry (1,116
case and 932 control subjects). Using these data, together
with data on a further 16 SNPs genotyped in two BCAC
studies (SEARCH and the combined Copenhagen studies
CPGS and CCHS), we imputed genotypes for 909 (out of
a possible 911) variants with MAF > 0.02 and imputation
r2 > 0.3 by using the January 2012 release of the 1000
Genomes Project as a reference.Potential Breast Cancer Risk Signals in European
Studies
Figure 1A shows the Manhattan plot of the 909 genotyped
and imputed SNPs (r2> 0.3) for overall breast cancer risk in
European studies. Genotype and association results for all
909 SNPs are presented in Table S4. Five hundred and
forty-one variants display association with overall breast
cancer risk at ptrend < 10
4 (Table S5). All associations are
consistent with a log-additive model.
In a forward stepwise conditional analysis using the
SNPs listed in Table S5, the best model included three
SNPs: (1) rs62355902 (conditional p value [pcond] ¼
8.6 3 1026), (2) rs113317823 (pcond ¼ 2.8 3 105), and
(3) rs11949391 (pcond ¼ 9.7 3 105). No significant evi-
dence of heterogeneity was observed among ORs for these
SNPs among studies of European ancestry (minimum
observed phet ¼ 0.14 and maximum l2 ¼ 19.3% for SNP
rs11949391; Figure S2). Each SNP remaining in the condi-
tional-analysis model indicates the existence of a separate
genetic risk signal (previously defined23 as an indepen-
dent set of correlated highly associated variants [iCHAV]),
each of which will contain at least one directly causal
variant.
The most significantly associated variant overall was
rs62355902 (OR per minor allele ¼ 1.21, 95% CI ¼ 1.19–
1.24, ptrend ¼ 9.5 3 1049). This was the most significant
of 15 strongly correlated SNPs (r2 > 0.93) lying within
a 50 kb interval (GRCh37 positions 56,003,831–
56,053,745, marked in red in Table S5); we designated
these SNPs as iCHAV1. These iCHAV1 SNPs all had likeli-
hood ratios of <100:1 in relation to the best candidate
SNP (rs62355902) and thus could not be excluded from
further analysis, given that they remained strong candi-
date causal variants on the basis of epidemiologicalAmerican Journal of Human Genetics 96, 5–20, January 8, 2015 9
Figure 1. Genetic Mapping and Chromatin State of the 5q11.2 Locus
(A) Manhattan plot of overall breast cancer risk in Europeans at the 5q11.2 locus. SNPs are plotted on the basis of their chromosomal
position on the x axis and p values (log10 values) for association. The span of the iCHAVs in terms of chromosomal location and p value
is displayed with shading, and candidate causal variants from the iCHAVare colored black. The lead SNPs from each iCHAV, the original
GWAS tag SNP (rs889312), and the three genes present in the region are shown. The dotted line intersects the y axis at p ¼ 108 and
indicates conventional genome-wide significance.
(B) The chromatin state of the 5q11.2 locus in humanmammary epithelial cells is shown with ENCODE ChIP-seq data from H3K4me3,
H3K4me2, H3k4me1, and DNaseI studies accessed from the UCSC Genome Browser. Transcription factor (TF) binding from ENCODE
ChIP-seq studies of 161 TFs in 91 cell lines is also displayed.evidence. After conditioning on iCHAV1 top SNP
rs62355902, the most strongly associated variant was
SNP rs113317823 (OR per minor allele ¼ 1.22, 95% CI ¼
1.18–1.26, ptrend ¼ 7.0 3 1025; conditional OR ¼ 1.12,
95% CI ¼ 1.05–1.20, pcond ¼ 2.8 3 105). One hundred
and seventy-two variants had likelihood ratios of <100:1
in relation to rs113317823, and these constituted
iCHAV2 (highlighted in shades of blue and yellow in Table
S5). SNP rs113317823 was partially correlated with
iCHAV1 top candidate rs62355902 (r2 ¼ 0.19), and this
added complexity to the subsequent analysis—this is
explored in more detail by the haplotype analysis
described below.
After adjustment for the top iCHAV1 (rs62355902) and
iCHAV2 (rs113317823) SNPs, the best remaining signifi-
cantly associated SNP was rs11949391 in iCHAV3 (OR
per minor allele ¼ 0.91, 95% CI ¼ 0.89–0.94, ptrend ¼
9.4 3 1012; conditional OR ¼ 0.95, 95% CI ¼ 0.92–0.98,
pcond ¼ 9.7 3 105). Four other SNPs had likelihood ratios
of <100:1 in relation to rs11949391 and were highly corre-
lated with rs11949391 (r2 R 0.95), but not with either of10 The American Journal of Human Genetics 96, 5–20, January 8, 201the top iCHAV1 or iCHAV2 SNPs (r2 < 0.04, marked in
yellow in Table S5), and these were thus candidate causal
variants for iCHAV3.
Effects on ERþ and ER Tumor Subtypes
Candidate causal SNPs in iCHAV1 were associated with
risks of both ERþ and ER disease (Table S5). However,
the OR was greater for ERþ disease (rs62355902, OR ¼
1.24, 95% CI ¼ 1.21–1.27) than for ER disease (OR ¼
1.10, 95% CI ¼ 1.05–1.15, p difference [pdiff] ¼ 1.5 3
105; Table 1). By contrast, the minor alleles of candidate
causal SNPs in iCHAV3 were protective against ERþ tumor
development (rs11949391, OR ¼ 0.90, 95% CI ¼ 0.87–
0.93, p ¼ 1.0 3 1010) but had no apparent effect on ER
tumor risk (OR ¼ 1.01, 95% CI ¼ 0.96–1.06, p ¼ 0.81,
pdiff ¼ 1.3 3 104; Table 1). The lead SNP in iCHAV2,
rs113317823, remained significantly associated with ERþ
tumor risk (pcond ¼ 9.7 3 105 after adjustment for
rs62355902), but not with ER tumor risk (pcond ¼
0.099), but the difference in the OR by ER subtype was
only borderline significant (pdiff ¼ 0.02; Table 1).5
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TheEffects of Haplotypes on Breast Cancer Risk
Whereas iCHAV1 and iCHAV3 represent sets of highly
correlated SNPs (r2 > 0.93 with the lead SNP), the set
of 173 SNPs, labeled iCHAV2, includes three subsets
defined according to their correlations with rs113317823
(iCHAV2) and rs62355902 (iCHAV1). These subsets are
(1) iCHAV2a (lead SNP rs113317823), which includes
90 SNPs correlated with rs113317823 (r2 > 0.53) and
iCHAV1 SNP rs62355902 (r2 ¼ 0.19–0.29) and is marked
in dark blue in Table S5; (2) iCHAV2b (lead SNP
rs62355899), which includes 66 SNPs independent of
rs113317823 (r2 % 0.01) but correlated with rs62355902
(r2 ¼ 0.59–0.62) (conditional OR ¼ 0.90, 95% CI ¼
0.86–0.95, pcond ¼ 3.0 3 105) and is marked in teal in
Table S5; and (3) iCHAV2c (lead SNP rs7721581), which
includes 17 SNPs that are modestly correlated with
rs113317823 (r2 ¼ 0.14–0.16) but independent of
rs62355902 (r2 % 0.01) (conditional OR ¼ 0.96, 95%
CI ¼ 0.93–0.98, pcond ¼ 4.8 3 104) and is marked in
pale blue Table S5.
To further clarify these association signals, we performed
haplotype analyses based on the lead SNPs from iCHAV1,
iCHAV2a, iCHAV2b, iCHAV2c, and iCHAV3. These five
SNPs define seven common haplotypes (Table 2). Two of
these—h5 (which carries the risk alleles of iCHAV1,
iCHAV2a, and iCHAV2b) and h6 (which carries the risk
alleles of iCHAV1 and iCHAV2b)—are strongly associated
with risk, although the risk is higher for haplotype h6
(p ¼ 1.66 3 1029). These results are consistent with the
observation that SNPs in iCHAV1 are the most strongly
associated with risk. They are also consistent with a
model in which either a SNP in iCHAV2a or iCHAV2c (in
combination with iCHAV1) increases risk or a SNP in
iCHAV2b reduces risk. These hypotheses are difficult to
distinguish given that the iCHAV1 risk allele never occurs
alone—it occurs in combination with either iCHAV2a or
iCHAV2c or with iCHAV2b, but not both. Some support
for the iCHAV1þiCHAV2a hypothesis is provided by the
fact that although rare, haplotypes h3 and h4, which
carry the risk alleles for iCHAV2a, but not iCHAV1, are
associated with increased risk. Evidence against the
iCHAV1þiCHAV2c hypothesis is provided by the fact
that h1, which carries the risk allele for iCHAV2c alone,
is not associated with increased risk. These observations
are consistent with the regression analyses, in which
iCHAV2c was less likely than iCHAV2a or iCHAV2b SNPs
to harbor a causal variant (likelihood ratio ~ 30:1 after
adjustment for iCHAV1). Haplotype h2, which carries the
minor allele of iCHAV3 SNP rs11949391, was associated
with a reduced ERþ (but not ER) breast cancer risk, consis-
tent with the effect of the iCHAV3 SNP in the regression
analysis.
We conclude that at least one of the 90 SNPs in iCHAV2a
(positions 56,001,002–56,270,717) or one of the 66 SNPs
in iCHAV2b (positions 55,998,085–56,183,743) is causally
related to risk together with a variant in iCHAV1 and a
variant in iCHAV3.American Journal of Human Genetics 96, 5–20, January 8, 2015 11
Table 2. Breast Cancer Risk in Europeans by Haplotypes of Five iCHAV Representative SNPs
Haplotypea
h0 h1 h2 h3 h4 h5 h6
iCHAV1b 1 1 1 1 1 2 2
iCHAV2ac 1 1 1 2 2 1 2
iCHAV2bd 1 1 1 1 1 2 1
iCHAV2ce 1 2 1 1 2 1 2
iCHAV3f 1 1 2 1 1 1 1
Frequency 0.52 0.12 0.15 0.02 0.01 0.11 0.05
Overall Breast Cancer Risk
OR – 1.01 0.95 1.08 1.05 1.16 1.31
95% CI – 0.99–1.05 0.92–0.97 0.99–1.17 0.99–1.17 1.12–1.20 1.25–1.37
p value – 4.50 3 101 2.08 3 104 7.57 3 102 3.81 3 101 2.00 3 1020 1.66 3 1029
ERþ Breast Cancer Risk
OR – 1.03 0.95 1.13 0.99 1.19 1.34
95% CI – 0.99–1.07 0.92–0.99 1.02–1.24 0.87–1.13 1.14–1.23 1.27–1.42
p value – 1.12 3 101 5.23 3 103 1.68 3 102 8.75 3 101 9.37 3 1020 3.74 3 1027
ER Breast Cancer Risk
OR – 1.04 1.04 1.08 1.17 1.1 1.15
95% CI – 0.98–1.11 0.98–1.10 0.92–1.27 0.96–1.42 1.04–1.18 1.05–1.25
p value – 2.08 3 101 1.67 3 101 3.45 3 101 1.12 3 101 1.82 3 103 3.64 3 103
1 represents major alleles, and 2 represents minor alleles in each SNP.
ah1–h6 are compared to h0 (the reference haplotype carrying the major alleles of all five SNPs).
biCHAV1 represents 15 SNPs, of which rs62355902 is the best candidate.
ciCHAV2a represents 90 SNPs that have r2 R 0.53 with rs113317823 and r2 ¼ 0.19–0.29 with rs62355902. rs113317823 is the best candidate.
diCHAV2b represents 66 SNPs that have r2 % 0.01 with rs113317823 and r2 ¼ 0.59–0.62 with rs62355902; rs62355899 is the best candidate.
eiCHAV2c represents 17 SNPs that have r2 ¼ 0.14–0.16 with rs113317823 and r2 % 0.01 with rs6235590; rs7721581 is the best candidate.
fiCHAV3 represents five SNPs, of which rs11949391 is the best candidate.Risk Associations in Asian and African American
Studies
Wetested all genotyped and imputed SNPswithMAF>0.02
and imputation r2 > 0.3 in the nine Asian studies (6,269
case and 6,624 control individuals; 1,045 SNPs) and the
two African American studies (1,116 case and 932 control
individuals; 1,601 SNPs) for association with overall breast
cancer risk. None reached genome-wide levels of signifi-
cance (p < 5 3 108), but the lead SNPs of each iCHAV
displayed compatible effects in all three ethnic groups.
This was most apparent for iCHAV2a SNP rs113317823
(European unadjusted OR ¼ 1.22, 95% CI ¼ 1.18–1.26,
ptrend ¼ 7.0 3 1025; Asian OR ¼ 1.19, 95% CI ¼ 1.11–
1.27, ptrend ¼ 1.4 3 105; African American OR ¼ 1.04,
95% CI ¼ 0.77–1.31, ptrend ¼ 0.78; Table S6).
Identification of PREs that Interact with the MAP3K1
Promoter
After the epidemiological analyses, 15 iCHAV1, 90
iCHAV2a, 66 iCHAV2b, and 5 iCHAV3 variants remained
as strong causal candidates (Figure 1A; Table S7), whereas
the data provide weaker support that iCHAV2c is causal.12 The American Journal of Human Genetics 96, 5–20, January 8, 201Because iCHAV2a and iCHAV2b were composed of a large
number of variants, we prioritized these for functional
analysis by using a threshold of pcond < 1 3 10
4 and
focused on the remaining 30 iCHAV2a and 10 iCHAV2b
variants, in addition to the iCHAV1 and iCHAV3 candi-
dates. Next, we examined whether these 62 iCHAV vari-
ants coincide with PREs that might affect gene expression.
Using publicly available ENCODE ChIP sequencing
(ChIP-seq) data from MCF7 and human mammary epithe-
lial cells, we identified regionsmarked by histonemodifica-
tions associated with transcriptional enhancers (mono- or
dimethylation of H3 lysine 4 [H3K4Me1 or H3K4Me2,
respectively] and acetylation of H3 lysine 27 [H3K27Ac])
or bound by transcription factors ER-a, FOXA1, or GATA3,
known to play a role in breast cancer. Next, we mined
RNA polymerase II ChIA-PET (chromatin-interaction anal-
ysiswithpaired-end tag sequencing) data, previously gener-
ated in MCF7 cells,24,25 and identified multiple long-range
chromatin interactions between discrete regions of the
iCHAV loci and thepromoter ofMAP3K1 (Figure S3).Conse-
quently, we performed 3C experiments to analyze interac-
tions between the MAP3K1 promoter and these regions5
Figure 2. Candidate Causal Variants Are Located in PREs that Interact with the MAP3K1 Promoter
(A) The candidate causal variants associated with breast cancer risk from iCHAV1, iCHAV2a, iCHAV2b, and iCHAV3 were mapped to
PREs at the 5q11.2 locus.
(B) PREs (highlighted) were identified with ChIP-seq data (H3K4Me1 studies in seven ENCODE cell lines [GM12878, H1-hESC, HSMM,
HUVEC, K562, NHEK, and NHLF]; H3K4Me1 and H3K4Me2 in MCF7 and humanmammary epithelial cells [HMECs]; and transcription
factors ER-a, FOXA1, and GATA3 inMCF7 cells) accessed from the UCSCGenome Browser. Regions cloned into reporter gene constructs
are also shown.
(C) 3C analysis of interactions between EcoRI fragments at the 5q11.2 locus, encompassing the PREs coinciding with candidate causal
variants, and the MAP3K1 promoter in Bre-80 cells (error bars represent SD, and a representative graph is shown).within 5q11.2. Using 3C in a normal mammary epithelial
cell line, Bre-80, we found several regions that interacted
with theMAP3K1 promoter (Figure 2C). Similar 3C profiles
were observed in two ERþ cell lines (MCF7 and T-47D) and
in ERMDA-MB231 breast cancer cells. (Figure S4).
PREs were defined as the loci encompassing functional
elements identified from the ENCODE data within a region
interacting with the MAP3K1 promoter. This analysis re-
vealed four PREs (PRE-A, PRE-B, PRE-C, and PRE-D) that
coincided with the iCHAV candidates prioritized for func-
tional analyses (Figure 2). Consistently, ENCODE ChIA-
PET data demonstrated that all four PREs interacted with
the MAP3K1 promoter (Figure S3A), but not with the pro-
moters of other nearby genes in MCF7 cells (Figure S3B).
It should be noted that all four PREs contained iCHAV2a
or iCHAV2b variants (pcond> 13 10
4) that were not prior-Theitized for functional analyses but could not be excluded as
causal candidates after the log-likelihood testing (Fig-
ure 2A). Furthermore, additional PREs, some containing
such iCHAV2a or iCHAV2b variants, were apparent at
this locus (Figure 2). Twenty-six percent of the 62 iCHAV
variants prioritized for functional analyses coincided
with a PRE. In contrast, only 16% of SNPs with a MAF in
the range of the MAF of the prioritized iCHAV variants
(dbSNP 138, MAF ¼ 0.04–0.18, accessed through the
UCSCGenome Browser) at this locus were located in a PRE.
The Risk Alleles of iCHAV1 Candidates rs74345699
and rs62355900 Further Induce PRE-C Enhancer
Activity after Estrogen Stimulation
For functional analysis of iCHAV1, we focused on 7 of the
15 candidate causal variants coinciding with a PRE (PRE-A,American Journal of Human Genetics 96, 5–20, January 8, 2015 13
Figure 3. Risk Alleles of iCHAV1 and iCHAV2a SNPs Enhance MAP3K1 Promoter Activity in Luciferase Reporter Assays
PRE-A, PRE-B, PRE-C, and PRE-D regions containing the major allelic variants of iCHAV1, iCHAV2a, and iCHAV2b SNPs were cloned
downstream of a MAP3K1-promoter-driven luciferase construct (promoter) for the creation of reference (ref) PRE constructs. Minor
allelic variants of the iCHAV1, iCHAV2a, and iCHAV2b SNPs were engineered into the constructs and are designated by the rs ID of
the corresponding SNP. Constructs containing minor allelic haplotypes (haplotype) were also generated. Cells were transiently trans-
fected with each of these constructs and assayed for luciferase activity after 24 hr.
(A and B) Results from assays of PRE-A (A) and PRE-B1 (B) in Bre-80 cells.
(C, E, and F) Results from assays of PRE-C (C), PRE-D (E), and PRE-B2 (F) in MCF7 cells under basal conditions.
(D) Results after estrogen induction ofMCF7 cells. For each reporter construct in this assay, the luciferase activity of estrogen-treated cells
was normalized to the activity of the corresponding vehicle-treated cells.
Error bars denote the SEM from three experiments performed in triplicate. p values were determined by repeated-measures ANOVA
followed by Dunnett’s multiple comparisons test (*p < 0.05 and **p < 0.01).PRE-B, and PRE-C; Figure 2). We first examined the effects
of these PREs onMAP3K1 promoter activity by cloning the
relevant genomic regions into luciferase reporter gene con-
structs containing the MAP3K1 promoter. All three of the
PREs had effects on MAP3K1 promoter activity: PRE-A
acted as a silencer and reduced promoter activity by 62%
(p ¼ 0.006) in Bre-80 cells (Figure 3A) and had a similar
but nonsignificant trend (p ¼ 0.056) in MCF7 cells
(Figure S5A). PRE-B1, a PRE-B subregion containing two
candidate variants, acted as an enhancer in Bre-80 cells
and increased promoter activity by 42% (p ¼ 0.047;
Figure 3B) but had no significant effect onMCF7 cells, indi-
cating that PRE-B1 might function in specific breast cell
types (Figure S5B). PRE-C acted as an enhancer and
increased MAP3K1 promoter activity by 90% (p ¼ 0.034)
in MCF7 cells (Figure 3C) and by 77% (p ¼ 0.034) in Bre-
80 cells (Figure S5D). Introduction of the iCHAV1 minor
alleles into the PRE-A, PRE-B1, and PRE-C reference con-14 The American Journal of Human Genetics 96, 5–20, January 8, 201structs did not detectably alter MAP3K1 promoter activity
(Figures 3A–3C; Figures S5A, S5B, and S5D).
ChIP-seq data from the ENCODE project indicate that at
least two different transcription factors implicated in estro-
gen signaling, FOXA1 and ER-a, bind within PRE-B1 and
PRE-C, respectively (Figure 2B). We thus tested whether
the iCHAV1 candidates within PRE-B1 and PRE-C confer
estrogen-dependent effects on MAP3K1 promoter activity.
We first confirmed that MAP3K1 expression was upregu-
lated by estrogen stimulation (Figure S6). Then, using
reporter assays, we examined the effects of estrogen induc-
tion on PRE-B1 and PRE-C by measuring the changes in
MAP3K1 promoter activity between estrogen-stimulated
and -unstimulated cells. We showed that compared with
the promoter construct, the PRE-C enhancer containing
the protective (major) alleles (Figure 3D), but not PRE-B1
(Figure S5C), had a significant induction in activity (72%,
p ¼ 0.012) after estrogen stimulation. Induction was5
23% (p ¼ 0.032) and 15% (p ¼ 0.011) greater in PRE-C en-
hancers containing the risk (minor) alleles of iCHAV1
candidate SNPs rs74345699 and rs62355900, respectively,
than in this reference PRE-C enhancer (Figure 3D). Of
note, neither of these candidates significantly affected
MAP3K1 promoter activity in the absence of estrogen.
The Risk Allele of iCHAV2a Candidate rs16886397 in
PRE-D Enhances MAP3K1 Promoter Activity
Of the 30 candidate causal variants for iCHAV2a at pcond <
1 3 104, one variant (rs77371588) coincided with a PRE
(Figure 2), and we thus prioritized this SNP for functional
analysis. Using luciferase reporter assays, we demonstrated
that the reference PRE-D acted as an enhancer of the
MAP3K1 promoter in Bre-80 cells and increased MAP3K1
promoter activity by 69% (p ¼ 0.013; Figure S7A). The
PRE-D enhancer containing the risk (minor) allele of
rs77371588 had 23% greater enhancer activity than the
reference PRE-D, but this effect did not reach statistical sig-
nificance (p ¼ 0.103; Figure S7A). By contrast, the same
PRE-D reference construct did not affectMAP3K1 promoter
activity in MCF7 cells, nor did the introduction of the risk
allele of rs77371588 into PRE-D significantly alter its activ-
ity (Figure 3E). Because we had generated the PRE-D
construct, it was straightforward to test rs16886397, an
additional iCHAV2a causal candidate located in PRE-D. It
did not reach the threshold for the functional prioritiza-
tion (pcond < 1 3 10
4) but did pass the likelihood-ratio
threshold of <100:1 for defining the causal iCHAV candi-
dates. In MCF7 cells, the construct containing the minor
(risk) allele of rs16886397 had 21% (p ¼ 0.049) greater
MAP3K1 promoter activity than the reference PRE-D
(Figure 3E), and thus rs16886397 appears to confer
enhancer activity on PRE-D. In Bre-80 cells, in contrast,
the minor allele of rs16886397 had no effect on PRE-D ac-
tivity (Figure S7A).
The Minor Allele of iCHAV2b Candidate rs62355881
Increases PRE-B2 Enhancer Activity
Of the ten iCHAV2b candidates at pcond < 1 3 10
4, three
variants coincided with PRE-B, and two flanked the bound-
aries of PRE-C (Figure 2). We prioritized the three variants
in PRE-B because these were the most compelling func-
tional candidates given their central location in several
functional elements (Figure 2B). Using reporter assays, we
demonstrated that the reference PRE-B2 construct (a
PRE-B subregion containing the iCHAV2b variants) acted
as an enhancer and increased the activity of the MAP3K1
promoter by 152% (p ¼ 0.032; Figure 3F) and 143% (p ¼
0.048; Figure S7B) in MCF7 and Bre-80 cells, respectively.
The introduction of the minor (potentially protective)
allele of the iCHAV2b candidate rs62355881 into the refer-
ence PRE-B2 construct led to a 29% (p ¼ 0.017) increase in
the enhancer activity of PRE-B2 in MCF7 cells, and the
haplotype construct containing the minor alleles of all
three iCHAV2b candidates demonstrated a similar effect
(p ¼ 0.030; Figure 3F). However, these effects were notTheseen in Bre-80 cells (Figure S7B), indicating another cell-
type-specific effect, and the other iCHAV2b candidates
did not have any effect on PRE-B2 activity in either cell
line (Figure 3F; Figure S7B).
The Protective Allele of iCHAV3 Candidate
rs17432750 Reduces PRE-B3 Enhancer Activity and
GATA3 Binding
Of the five iCHAV3 candidates, we focused on two variants
coinciding with PRE-B3 (Figure 2B) for functional analysis.
Using reporter assays, we demonstrated that the reference
PRE-B3 construct (a third subregion of PRE-B), containing
the risk (major) iCHAV3 alleles, increased MAP3K1 pro-
moter activity by 166% (p ¼ 0.041; Figure 4A) and 110%
(p ¼ 0.035; Figure S8A) in Bre-80 and MCF7 cells, respec-
tively. Reversing the orientation of PRE-B3 in the reporter
gene construct had no effect on its activity in either cell
line (Figures S8B and S8C), indicating that it acts as a
typical enhancer. Next, we introduced the protective
(minor) alleles of the iCHAV3 candidates into the reference
PRE-B3 construct. The protective A allele of rs17432750
had a repressive effect and reduced PRE-B3 enhancer activ-
ity by 43% (p ¼ 0.024; Figure 4A) in Bre-80 cells. The same
allele had a similar but nonsignificant effect (p ¼ 0.150) in
MCF7 cells (Figure S8A). By contrast, the protective allele
of the second iCHAV3 candidate, rs11956804, had no sig-
nificant effect on enhancer activity in either cell line
(Figure 4A; Figure S8A). The haplotype construct contain-
ing both iCHAV3 variants also had no significant effect
on enhancer activity (Figure 4A; Figure S8A), suggesting
the possibility of an interaction between the two iCHAV3
minor alleles in this construct.
We observed fromMCF7ChIP-seq data that a region con-
taining rs17432750 bound the transcription factor GATA3
(Figure 2B) and that the sequence around rs17432750
showed homology to the GATA3 position weight matrix
(Figure 4B). Using GATA3 ChIP assays, followed by qPCR
detection,weconfirmedthat compared to theCCND1nega-
tive control, the sequence surrounding this SNP showed
consistent 2-fold enrichment in precipitated DNA (Fig-
ure 4C). We also tested the allele specificity of GATA3 bind-
ing by using a TaqMan genotyping assay for rs17432750 on
ChIP samples from MCF7 cells. The allelic-discrimination
plot of these data showed an enrichment of the risk (major)
C allele in the GATA3 ChIP samples (Figure 4D). The ratio
of the two alleles in three independent ChIP experiments
indicated 3.7-fold greater GATA3 binding to the risk C
allele than to the protective A allele in MCF7 cells.
To determine whether differential GATA3 transcription
factor binding might explain the effects of rs17432750 in
the reporter assays, we used siRNA to knock down GATA3
and found the enhancer activity of the reference PRE-B3
construct, containing the risk C allele, to be reduced by
33% in Bre-80 cells (p ¼ 0.001; Figure 4E). GATA3 knock-
down had no effect on the construct containing the pro-
tective A allele of rs17432750 or the MAP3K1 promoter
alone (Figure 4E). Diminished GATA3 binding to theAmerican Journal of Human Genetics 96, 5–20, January 8, 2015 15
Figure 4. The Protective Allele of iCHAV3 SNP rs17432750 Demonstrates Diminished PRE-B3 Enhancer Activity in Luciferase Reporter
Assays and Reduced GATA3 Binding in ChIP Analysis
(A) The PRE-B3 region containing themajor allelic variants of iCHAV3 SNPs was cloned downstream of aMAP3K1-promoter-driven lucif-
erase construct (promoter) for the creation of reference (ref) PRE constructs. Minor allelic variants of iCHAV3 SNPs were engineered into
the constructs and are designated by the rs ID of the corresponding SNP. A construct containing theminor allelic haplotypes (haplotype)
was also generated. Bre-80 cells were transiently transfected with each of these constructs and assayed for luciferase activity after 24 hr.
Error bars denote SEM from three experiments performed in triplicate. p values were determined by repeated-measures ANOVA followed
by Dunnett’s multiple comparisons test (*p < 0.05).
(B) Position weight matrix of GATA3 is shown in relation to the negative strand of the sequences surrounding rs17432750.
(C) GATA3 ChIP assays demonstrate enrichment of rs17432750 in relation to the CCND1 negative control. A GATA3 site from the ER-a
enhancer was included as a positive control. Results from two biological repeats are shown, and error bars denote SD of three technical
repeats.
(D) Genotyping of rs17432750 in MCF7 genomic DNA versus MCF7 GATA3-ChIP DNA. Homozygous cell lines ZR751 (C/C), T47D
(C/C), and MDA-MB-468 (A/A) and no template controls (NTCs) were included as references for the assay. The risk (major) C allele
was preferentially precipitated in the ChIP experiment.
(E) Luciferase assay in Bre-80 cells shows the effect of GATA3 siRNA silencing on the activity of theMAP3K1 promoter alone (promoter)
and with PRE-B3 constructs containing the C allele (ref PRE-B3) and protective A (minor) allele rs17432750 (rs17432750). Error bars
denote SEM from three experiments performed in triplicate. p values were determined by two-way repeated-measures ANOVA followed
by either Sidak’s multiple-comparisons test (to analyze the effect of GATA3 knockdown within constructs) or Dunnett’s multiple-
comparisons test (to analyze differences in activity between constructs) (*p < 0.05, **p < 0.01, and ***p < 0.001). The level of GATA3
knockdown is shown in Figure S9.protective A allele thus appears to be responsible for the
observed decrease in PRE-B3 enhancer activity under basal
conditions (Figure 4A).
eQTL Analyses
Given the findings of these functional studies, an obvious
hypothesis is that the candidate causal variants in the16 The American Journal of Human Genetics 96, 5–20, January 8, 201iCHAVs are associated with differences in expression of
MAP3K1 and possibly other local genes in normal breast
cells. We therefore explored potential eQTL associations
between all locus SNPs and genes lying within ~1 Mb of
the locus in 135 normal breast tissue samples from the
METABRIC study and 56 further normal breast samples
from the TCGA study. Summary results for representative5
SNPs from the three iCHAVs are presented in Table S8.
None of the iCHAV representative SNPs showed detectable
differences in MAP3K1 expression in this data set. This
locus had a positive control eQTL: SNP rs832402 was the
most strongly associated SNP in that it showed SETD9
expression in both METABRIC (p ¼ 5.93 3 109) and
TCGA (p ¼ 1.96 3 107) studies, but it was not a
strong candidate SNP for breast cancer risk (pcond ¼
1.46 3 103). The positive control SNP was in iCHAV2c
(correlated with lead SNP rs7721581 at r2 ¼ 0.74), and
SNP rs7721581 was consequently also associated, although
less significantly, with SETD9 expression (METABRIC p ¼
4.38 3 108; TCGA p ¼ 2.78 3 104). However, because
none of the other representative iCHAV SNPs were associ-
ated with SETD9 expression, it appears unlikely that
detectable SETD9 expression differences in normal breast
cells are the underlying cause of breast cancer generated
by the candidate functional variants we have identified.Discussion
In this fine-scale mapping study, we found clear evidence
of at least three independent breast cancer risk variants
in European women: SNPs in iCHAV1 and iCHAV2 each
had the greatest effects on breast cancer in the unadjusted
analysis in that their minor alleles conferred increased risks
of 25%–30% for ERþ and ~10% for ER tumor develop-
ment, whereas the minor alleles of SNPs in iCHAV3 had
a protective effect of ~10% against ERþ breast cancer but
no apparent effect on ER tumor risk (Table 1). The origi-
nally detected GWAS tag SNP, rs889312, was most
correlated with iCHAV1 (r2 ¼ 0.5) and could be excluded
from causality within iCHAV1 with a likelihood ratio
of >1021:1. Within iCHAV2, we additionally found evi-
dence of three subsets of variants (iCHAV2a, iCHAV2b,
and iCHAV2c) with a range of effects. The epidemiological
analyses suggest that iCHAV2c is least likely to be causally
related to risk, and we conclude that at least one of the var-
iants in iCHAV2a or iCHAV2b is functional. It should be
noted that the correlations between candidate causal
SNPs in iCHAV1 and iCHAV2 have added to this analysis
and its interpretation a level of complexity that we have
not recognized in previous fine-scale mapping studies of
breast cancer risk loci.
We separately identified at least four 5q11.2 PREs that
contain iCHAV candidate variants and interact with the
MAP3K1 promoter in normal and cancermammary epithe-
lial cells. 3C analysis indicates that there are long-range
chromatin interactions between these PREs and the
MAP3K1 promoter, whereas interactions between the
PREs and the promoters of other nearby genes are not
evident from available ChIA-PET studies.24,25 Although
we cannot rule out interactions between the iCHAVs and
the promoters of other genes in the region, such as
SETD9 or MIER3 (a proposed candidate gene for this risk
locus26), we propose that MAP3K1 is the likely targetThegene of the 5q11.2 breast cancer susceptibility locus.
Consistent with this proposition and our analyses, Corra-
din et al. identified an enhancer (chr5: 56,052,477–
56,053,943) that coincides with the element we have
termed PRE-C and that is predicted to regulate MAP3K1
on the basis of correlation between cell-type-specific
H3K4me1 modification and MAP3K1 expression data.27
Our reporter assays indicate that PRE-B, PRE-C, and
PRE-D act as enhancers, whereas PRE-A is a silencer of
the MAP3K1 promoter. Having identified these regulatory
elements, we investigated whether the iCHAV candidate
causal variants within these PREs detectably modify their
regulatory activity. We found that (1) the risk alleles of
two iCHAV1 candidates, rs74345699 and rs62355900, in
the PRE-C enhancer acted to further induce MAP3K1 pro-
moter activity in breast cancer cells under estrogen stimu-
lation; (2) the risk allele of iCHAV2a candidate rs16886397
in PRE-D conferred enhancer activity on this PRE for
MAP3K1 promoter activity in breast cancer cells; (3) the
potentially protective allele of iCHAV2b candidate
rs62355881 in the PRE-B2 enhancer increased MAP3K1
promoter activity in breast cancer cells; and (4) the protec-
tive allele of iCHAV3 SNP rs17432750 diminished the
enhancer activity of PRE-B3 for the MAP3K1 promoter in
these cells.
Because of experimental constraints, we were only able
to examine the functions of a minority of the iCHAV
causal candidates, and we thus cannot exclude the pres-
ence of more functional variants across the recognizable
iCHAVs. Of the candidates we examined in reporter gene
assays, four support a hypothesis that alleles that increase
MAP3K1 expression also increase breast cancer risk.
Currently, the allelic effects of a fifth candidate, iCHAV2b
SNP rs62355881, might be inconsistent with this hypoth-
esis given that the conditional analysis suggests that
iCHAV2b has a protective effect. However, we do not
have clear epidemiological evidence that iCHAV2b has
an individual effect on risk: iCHAV2b was only observed
in the presence of iCHAV1, which acted in combination
on the same haplotype to increase breast cancer risk, and
we could not test such iCHAV haplotype effects in reporter
gene assays given the number of candidates and the size of
the region they encompass.
Consistent with our hypothesis that candidate causal
risk alleles act by increasing transcriptional activation of
MAP3K1, Godde et al. have recently demonstrated that up-
regulation of MAP kinase activity in mouse mammary
basal progenitor cells is associated with ductal hyperplasia
and accelerated tumor progression.28 This hypothesis is
also supported by one known function of MEKK1: knock-
down of MAP3K1 in human breast cancer cells reduces tu-
mor invasiveness and progression in a mouse model.29
Furthermore, studies have shown that MEKK1 has an anti-
apoptotic effect and enhances cancer cell survival,30,31
although upon stress stimulus, caspase cleavage of the pro-
tein generates a fragment that plays a proapoptotic role.6,7
These dual functions of MEKK1 suggest that it has aAmerican Journal of Human Genetics 96, 5–20, January 8, 2015 17
complex role in cell-fate decisions. In this context, it is
intriguing that somatic MAP3K1 driver mutations, found
in tumor sequencing studies, are mostly truncating and
are predicted to disrupt MEKK1 signaling,11 given that
inactivation of the kinase domain at the protein terminus
reduces apoptotic responses in cells exposed to stress.7
Thus, it appears that germline cancer risk alleles act by
increasing MAP3K1 expression, but once a tumor has
developed, somatic mutations drive cancer progression
by disruptingMEKK1 signaling within the tumor. Dysregu-
lation of MAP3K1 expression or MEKK1 function might
thus promote tumorigenesis by perturbing a balance
between cell apoptosis and survival. Similar conflicting
effects of germline risk variants and somatic mutations
have been observed at other breast cancer risk loci. For
example, CCND1 is frequently amplified in breast tumors,
and here, overexpression appears to play an important role
in breast cancer pathogenesis,32 even though germline
breast cancer risk alleles at 11q13 reduce CCND1 transcrip-
tional activity.17 Amplification of TERT (MIM 187270) is
also common within breast and other tumors,33 but again,
germline breast cancer risk alleles reduce TERT transcrip-
tional activity.34 These observations therefore challenge
the notion that variants at loci such as 5q11.2 act in the
same manner as somatic tumor driver mutations to confer
germline risk of tumor development.
iCHAV1 spans multiple PREs (PRE-A, PRE-B, and PRE-C)
and is consistent with a recent proposal that genetic sus-
ceptibility to common diseases can be explained by multi-
ple enhancer variants that are in linkage disequilibrium,
that each have modest effects on gene expression, and
that cooperatively act to alter gene expression.27 There is
also some suggestion from the haplotype data that
iCHAV2a, which is in linkage disequilibrium (r2 ¼ 0.19–
0.29) with iCHAV1, might have a cooperative effect on
risk in combination with iCHAV1. The modest effect sizes
observed in the reporter assays for iCHAV1 and iCHAV2a
variants might be a consequence of the fact that, as a result
of size limitations of reporter gene constructs, we could not
examine these variants in combination.
Some SNP effects in our reporter assays were suggestive
of cell-line and stimulus dependence, highlighting the
importance of cellular and environmental context in the
assessment of SNP functionality.23 Similarly, we defined
our PREs on the basis of chromatin modification and
conformation states, both of which can change during
development or in response to stimulus. Additionally,
the effects of some SNPs might not have been observed
because plasmid reporter gene constructs do not reflect
the native genomic context or the chromatin or methyl-
ation state of genomic DNA. The chromatin state of tran-
siently transfected DNA, for example, is considered to be
more open and disorganized than the corresponding chro-
matin in the native genomic context and might not have
the repressive chromatin structures, found in genomic
DNA, that inhibit binding of ubiquitous transcription fac-
tors.35 A disorganized chromatin state might explain the18 The American Journal of Human Genetics 96, 5–20, January 8, 201inconsistent effect of rs17432750 in the PRE-B3 constructs
(Figure 4A). The abrogation of the effect of rs17432750 in
the haplotype construct suggests some interaction or coop-
erative effect of the minor alleles of rs17432750 and
rs11956804 to enhance promoter activity. This effect
might be possible as a result of the more open and permis-
sive chromatin structures associated with transfected
plasmid DNA.
It is noteworthy that, in available normal breast tissue,
the top candidate causal variants showed no association
with MAP3K1 expression, although iCHAV2c variants
were associated with significant differences in SETD9
mRNA levels. Similarly, normal-breast-tissue-eQTL studies
with strong candidate causal variants at the 11q13,17
10q26,15 2q35,36 and 5p15.3334 breast cancer risk loci
have indicated that available normal breast samples might
be inappropriate for these studies. Sample sizes are large
enough for detecting significant eQTLs at these loci, but
those detected do not appear to drive breast cancer risk.
It is possible that tissue-heterogeneity-, developmental-
stage-, or stimulus-dependent effects prevent the detection
of risk-driving eQTLs in currently available normal breast
samples. Indeed, the finding that upregulation of MAP ki-
nase activity in mammary progenitor cells is associated
with mammary tumorigenesis28 suggests that increased
MAP3K1 expression in specific breast cell populations,
possibly at a specific point in time, could drive breast can-
cer risk.
Studies on transcription factor binding indicate that the
C (risk) allele of rs17432750 preferentially binds GATA3
over the A (protective) allele. Increased binding of the C
allele by GATA3 appears to explain the activity of the
PRE-B3 enhancer in which it is located (Figure 4E). These
findings suggest that SNP rs17432750 is a strong causal
candidate for the protective effect of iCHAV3. The
transcription factor GATA3 has multiple regulatory roles
and can affect histone modifications associated with en-
hancers and the binding of other breast-cancer-related
transcription factors, such as ER-a and FOXA1.37 We
have previously identified GATA3 to be a mediator of
breast cancer risk across multiple loci,38 specifically at the
11q13 locus.17
In conclusion, we have found evidence of the existence
of at least three breast cancer risk iCHAVs that partially
coincide with four MAP3K1 regulatory elements at
5q11.2. Genetic epidemiological studies within BCAC
reduced the catalog of potentially causal variants from
909 to 193 candidates within five iCHAVs, of which at least
three must be functional. Functional studies on candidates
that lie within the identified regulatory elements have
shown that the effects of strong candidate cancer risk
alleles in iCHAV1, iCHAV2a, and iCHAV3 are compatible
with the hypothesis that they act via increased expression
of MAP3K1. Moreover, the function of MEKK1 suggests
that increased expression might alter the balance between
apoptosis and cell survival in breast cancer cells, thus ex-
plaining the risks conferred by the candidate alleles.5
Supplemental Data
Supplemental Data include Supplemental Acknowledgments,
nine figures, and eight tables and can be found with this article
online at http://dx.doi.org/10.1016/j.ajhg.2014.11.009.
Received: July 9, 2014
Accepted: November 17, 2014
Published: December 18, 2014Web Resources
The URLs for data presented herein are as follows:
1000 Genomes, http://www.1000genomes.org/
Online Mendelian Inheritance in Man (OMIM), http://www.
omim.org
R package, http://www.bios.unc.edu/~weisun/software/eMap
UCSC Genome Browser, http://genome.ucsc.eduReferences
1. Easton, D.F., Pooley, K.A., Dunning, A.M., Pharoah, P.D.,
Thompson, D., Ballinger, D.G., Struewing, J.P., Morrison, J.,
Field, H., Luben, R., et al.; SEARCH collaborators; kConFab;
AOCS Management Group (2007). Genome-wide association
study identifies novel breast cancer susceptibility loci. Nature
447, 1087–1093.
2. Michailidou, K., Hall, P., Gonzalez-Neira, A., Ghoussaini, M.,
Dennis, J., Milne, R.L., Schmidt, M.K., Chang-Claude, J., Boje-
sen, S.E., Bolla, M.K., et al.; Breast and Ovarian Cancer Suscep-
tibility Collaboration; Hereditary Breast and Ovarian Cancer
Research Group Netherlands (HEBON); kConFab Investiga-
tors; Australian Ovarian Cancer Study Group; GENICA
(Gene Environment Interaction and Breast Cancer in Ger-
many) Network (2013). Large-scale genotyping identifies 41
new loci associated with breast cancer risk. Nat. Genet. 45,
353–361, e1–e2.
3. Broeks, A., Schmidt, M.K., Sherman,M.E., Couch, F.J., Hopper,
J.L., Dite, G.S., Apicella, C., Smith, L.D., Hammet, F., Southey,
M.C., et al.; Genica Network; kConFab; AOCS (2011). Low
penetrance breast cancer susceptibility loci are associated
with specific breast tumor subtypes: findings from the Breast
Cancer Association Consortium. Hum. Mol. Genet. 20,
3289–3303.
4. Antoniou, A.C., Spurdle, A.B., Sinilnikova, O.M., Healey, S.,
Pooley, K.A., Schmutzler, R.K., Versmold, B., Engel, C., Meindl,
A., Arnold, N., et al.; Kathleen Cuningham Consortium for
Research into Familial Breast Cancer; OCGN; Swedish
BRCA1 and BRCA2 study collaborators; DNA-HEBON collabo-
rators; EMBRACE; GEMO; CIMBA (2008). Common breast
cancer-predisposition alleles are associated with breast cancer
risk in BRCA1 and BRCA2 mutation carriers. Am. J. Hum.
Genet. 82, 937–948.
5. Keshet, Y., and Seger, R. (2010). The MAP kinase signaling
cascades: a system of hundreds of components regulates a
diverse array of physiological functions. Methods Mol. Biol.
661, 3–38.
6. Schlesinger, T.K., Bonvin, C., Jarpe, M.B., Fanger, G.R., Cardi-
naux, J.R., Johnson, G.L., andWidmann, C. (2002). Apoptosis
stimulated by the 91-kDa caspase cleavage MEKK1 fragment
requires translocation to soluble cellular compartments.
J. Biol. Chem. 277, 10283–10291.The7. Widmann, C., Gerwins, P., Johnson, N.L., Jarpe, M.B., and
Johnson, G.L. (1998). MEK kinase 1, a substrate for DEVD-
directed caspases, is involved in genotoxin-induced apoptosis.
Mol. Cell. Biol. 18, 2416–2429.
8. Alarcon-Vargas, D., Tansey, W.P., and Ronai, Z. (2002). Regula-
tion of c-myc stability by selective stress conditions and
by MEKK1 requires aa 127-189 of c-myc. Oncogene 21,
4384–4391.
9. Fuchs, S.Y., Adler, V., Pincus, M.R., and Ronai, Z. (1998).
MEKK1/JNK signaling stabilizes and activates p53. Proc.
Natl. Acad. Sci. USA 95, 10541–10546.
10. Clarke, N., Arenzana, N., Hai, T., Minden, A., and Prywes, R.
(1998). Epidermal growth factor induction of the c-jun pro-
moter by a Rac pathway. Mol. Cell. Biol. 18, 1065–1073.
11. Stephens, P.J., Tarpey, P.S., Davies, H., Van Loo, P., Greenman,
C., Wedge, D.C., Nik-Zainal, S., Martin, S., Varela, I., Bignell,
G.R., et al.; Oslo Breast Cancer Consortium (OSBREAC)
(2012). The landscape of cancer genes and mutational pro-
cesses in breast cancer. Nature 486, 400–404.
12. Nordgard, S.H., Johansen, F.E., Alnaes, G.I., Naume, B., Børre-
sen-Dale, A.L., and Kristensen, V.N. (2007). Genes harbouring
susceptibility SNPs are differentially expressed in the breast
cancer subtypes. Breast Cancer Res. 9, 113.
13. Abecasis, G.R., Altshuler, D., Auton, A., Brooks, L.D., Durbin,
R.M., Gibbs, R.A., Hurles, M.E., and McVean, G.A.; 1000 Ge-
nomes Project Consortium (2010). A map of human genome
variation from population-scale sequencing. Nature 467,
1061–1073.
14. Abecasis, G.R., Auton, A., Brooks, L.D., DePristo, M.A., Dur-
bin, R.M., Handsaker, R.E., Kang, H.M., Marth, G.T., and
McVean, G.A.; 1000 Genomes Project Consortium (2012).
An integrated map of genetic variation from 1,092 human ge-
nomes. Nature 491, 56–65.
15. Meyer, K.B., O’Reilly, M., Michailidou, K., Carlebur, S.,
Edwards, S.L., French, J.D., Prathalingham, R., Dennis, J.,
Bolla, M.K., Wang, Q., et al.; GENICA Network; kConFab
Investigators; Australian Ovarian Cancer Study Group
(2013). Fine-scale mapping of the FGFR2 breast cancer risk
locus: putative functional variants differentially bind FOXA1
and E2F1. Am. J. Hum. Genet. 93, 1046–1060.
16. Tan-Wong, S.M., French, J.D., Proudfoot, N.J., and Brown,
M.A. (2008). Dynamic interactions between the promoter
and terminator regions of the mammalian BRCA1 gene.
Proc. Natl. Acad. Sci. USA 105, 5160–5165.
17. French, J.D., Ghoussaini, M., Edwards, S.L., Meyer, K.B., Mi-
chailidou, K., Ahmed, S., Khan, S., Maranian, M.J., O’Reilly,
M., Hillman, K.M., et al.; GENICA Network; kConFab Investi-
gators (2013). Functional variants at the 11q13 risk locus for
breast cancer regulate cyclin D1 expression through long-
range enhancers. Am. J. Hum. Genet. 92, 489–503.
18. Prall, O.W., Sarcevic, B., Musgrove, E.A., Watts, C.K., and
Sutherland, R.L. (1997). Estrogen-induced activation of Cdk4
and Cdk2 during G1-S phase progression is accompanied by
increased cyclin D1 expression and decreased cyclin-depen-
dent kinase inhibitor association with cyclin E-Cdk2. J. Biol.
Chem. 272, 10882–10894.
19. Schmidt, D., Wilson, M.D., Spyrou, C., Brown, G.D., Hadfield,
J., and Odom, D.T. (2009). ChIP-seq: using high-throughput
sequencing to discover protein-DNA interactions. Methods
48, 240–248.
20. Curtis, C., Shah, S.P., Chin, S.F., Turashvili, G., Rueda, O.M.,
Dunning, M.J., Speed, D., Lynch, A.G., Samarajiwa, S., Yuan,American Journal of Human Genetics 96, 5–20, January 8, 2015 19
Y., et al.; METABRIC Group (2012). The genomic and tran-
scriptomic architecture of 2,000 breast tumours reveals novel
subgroups. Nature 486, 346–352.
21. Cancer Genome Atlas Network (2012). Comprehensive mo-
lecular portraits of human breast tumours. Nature 490, 61–70.
22. Marchini, J., and Howie, B. (2010). Genotype imputation
for genome-wide association studies. Nat. Rev. Genet. 11,
499–511.
23. Edwards, S.L., Beesley, J., French, J.D., and Dunning, A.M.
(2013). Beyond GWASs: illuminating the dark road from asso-
ciation to function. Am. J. Hum. Genet. 93, 779–797.
24. Li, G., Ruan, X., Auerbach, R.K., Sandhu, K.S., Zheng, M.,
Wang, P., Poh, H.M., Goh, Y., Lim, J., Zhang, J., et al. (2012).
Extensive promoter-centered chromatin interactions provide
a topological basis for transcription regulation. Cell 148,
84–98.
25. Fullwood, M.J., Liu, M.H., Pan, Y.F., Liu, J., Xu, H., Mohamed,
Y.B., Orlov, Y.L., Velkov, S., Ho, A., Mei, P.H., et al. (2009). An
oestrogen-receptor-alpha-bound human chromatin interac-
tome. Nature 462, 58–64.
26. denDekker, A.D., Xu, X., Vaughn, M.D., Puckett, A.H., Gard-
ner, L.L., Lambring, C.J., Deschenes, L., and Samuelson, D.J.
(2012). Rat Mcs1b is concordant to the genome-wide associa-
tion-identified breast cancer risk locus at human 5q11.2 and
MIER3 is a candidate cancer susceptibility gene. Cancer Res.
72, 6002–6012.
27. Corradin, O., Saiakhova, A., Akhtar-Zaidi, B., Myeroff, L., Wil-
lis, J., Cowper-Sal lari, R., Lupien, M., Markowitz, S., and Sca-
cheri, P.C. (2014). Combinatorial effects of multiple enhancer
variants in linkage disequilibrium dictate levels of gene
expression to confer susceptibility to common traits. Genome
Res. 24, 1–13.
28. Godde, N.J., Sheridan, J.M., Smith, L.K., Pearson, H.B., Britt,
K.L., Galea, R.C., Yates, L.L., Visvader, J.E., and Humbert,
P.O. (2014). Scribble modulates the MAPK/Fra1 pathway to
disrupt luminal and ductal integrity and suppress tumour for-
mation in the mammary gland. PLoS Genet. 10, e1004323.
29. Cuevas, B.D., Winter-Vann, A.M., Johnson, N.L., and John-
son, G.L. (2006). MEKK1 controls matrix degradation and
tumor cell dissemination during metastasis of polyoma
middle-T driven mammary cancer. Oncogene 25, 4998–5010.
30. Hirano, T., Shino, Y., Saito, T., Komoda, F., Okutomi, Y.,
Takeda, A., Ishihara, T., Yamaguchi, T., Saisho, H., and Shira-20 The American Journal of Human Genetics 96, 5–20, January 8, 201sawa, H. (2002). Dominant negative MEKK1 inhibits survival
of pancreatic cancer cells. Oncogene 21, 5923–5928.
31. Nawata, R., Yujiri, T., Nakamura, Y., Ariyoshi, K., Takahashi, T.,
Sato, Y., Oka, Y., and Tanizawa, Y. (2003). MEK kinase 1 medi-
ates the antiapoptotic effect of the Bcr-Abl oncogene through
NF-kappaB activation. Oncogene 22, 7774–7780.
32. Arnold, A., and Papanikolaou, A. (2005). Cyclin D1 in breast
cancer pathogenesis. J. Clin. Oncol. 23, 4215–4224.
33. Cao, Y., Bryan, T.M., and Reddel, R.R. (2008). Increased copy
number of the TERT and TERC telomerase subunit genes in
cancer cells. Cancer Sci. 99, 1092–1099.
34. Bojesen, S.E., Pooley, K.A., Johnatty, S.E., Beesley, J., Michaili-
dou, K., Tyrer, J.P., Edwards, S.L., Pickett, H.A., Shen, H.C.,
Smart, C.E., et al.; Australian Cancer Study; AustralianOvarian
Cancer Study; Kathleen Cuningham Foundation Consortium
for Research into Familial Breast Cancer (kConFab); Gene
Environment Interaction and Breast Cancer (GENICA); Swed-
ish Breast Cancer Study (SWE-BRCA); Hereditary Breast and
Ovarian Cancer Research Group Netherlands (HEBON);
Epidemiological study of BRCA1 & BRCA2 Mutation Carriers
(EMBRACE); Genetic Modifiers of Cancer Risk in BRCA1/2
Mutation Carriers (GEMO) (2013). Multiple independent var-
iants at the TERT locus are associated with telomere length
and risks of breast and ovarian cancer. Nat. Genet. 45, 371–
384, e1–e2.
35. Smith, C.L., andHager, G.L. (1997). Transcriptional regulation
of mammalian genes in vivo. A tale of two templates. J. Biol.
Chem. 272, 27493–27496.
36. Ghoussaini, M., Edwards, S.L., Michailidou, K., Nord, S.,
Cowper-Sal Lari, R., Desai, K., Kar, S., Hillman, K.M., Kauf-
mann, S., Glubb, D.M., et al.; Australian Ovarian Cancer
Management Group; Australian Ovarian Cancer Manage-
ment Group (2014). Evidence that breast cancer risk at the
2q35 locus is mediated through IGFBP5 regulation. Nat.
Commun. 4, 4999.
37. Theodorou, V., Stark, R., Menon, S., and Carroll, J.S. (2013).
GATA3 acts upstream of FOXA1 in mediating ESR1 binding
by shaping enhancer accessibility. Genome Res. 23, 12–22.
38. Fletcher, M.N.C., Castro, M.A.A., Wang, X., de Santiago, I.,
O’Reilly, M., Chin, S.-F., Rueda, O.M., Caldas, C., Ponder,
B.A.J., Markowetz, F., and Meyer, K.B. (2013). Master regula-
tors of FGFR2 signalling and breast cancer risk. Nat. Commun.
4, 2464.5
